Milestone Scientific's CompuFlo(R) Epidural System, Wand(R) STA Dental System and Cosmetic Instrument Featured in Television Broadcasts and in Premier Online News Journal

Reflects expanding health and medical media coverage of Milestone's technologies

LIVINGSTON, NJ--(Marketwired - November 28, 2017) - Milestone Scientific Inc. (NYSE American: MLSS) (NYSE MKT: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its Wand® STA Dental and CompuFlo® Epidural systems were featured in separate television news broadcasts in Pittsburgh and South Florida, respectively. In addition, news of the commercial launch of the newly developed cosmetic instrument for delivery of botulinum toxin (such as Botox® and Dysport®) was picked up by Drug Delivery Business News. The broadcasts and news reporting reflect the growing coverage the Company's technologies are receiving among mainstream regional, health and medical news outlets.

The Pittsburgh KDKA-TV broadcast featured the Wand® STA Dental system, which was incorporated into the treatment protocols at the famed Pittsburgh Children's Hospital, and can be viewed at: https://ir.milestonescientific.com/videos/video/743/the-wand-on-pittsburgh-kdka-tv

The CompuFlo® Epidural system coverage was featured on the West Palm Beach CBS Television affiliate WPEC and can be viewed at: https://ir.milestonescientific.com/videos/video/744/compuflo-epidural-on-west-palm-beach-cbs-wpec-tv. Similar reports were broadcast on West Palm Beach's Fox Television affiliate WFLX and ABC affiliate WPBF.

Drug Delivery Business News posted the story on the commercial launch of the cosmetic instrument on November 20th at: http://www.drugdeliverybusiness.com/milestone-scientific-plans-launch-botox-injection-device/. Drug Delivery Business News is the latest site in the MassDevice.com Life Sciences Network.

"The recent news coverage of our instruments is evidence of the growing interest in our proprietary Dynamic Pressure Sensing Technology®," commented Leslie Bernhard, Chairman of the Board, and Interim Chief Executive Officer. "We will continue to build exposure among independent third-party health and medical media whose favorable reports demonstrate to their audiences the benefits of our technology for both patients and physicians."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technologies. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. For more information please visit our website:www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Advertisement